50 results about "Pro-apoptosis" patented technology

The invention discloses lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder. The preservation number of the lactobacillus mucilaginosus is CGMCC (China General Microbiological Culture Collection Center) No.31453. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is not hemolyzed, is sensitive to various common antibiotics and has strong lactic acid production capacity, and fermented supernate of the strain has strong growth inhibition capacity on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae and gardnerella vaginalis and can be used for producing lactic acid. The compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of bioactive substances such as amino acids and derivatives thereof, fatty acids and steroids in fermentation liquor can be greatly increased, the strain has an obvious anti-inflammatory effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in functional food and biological agents, but also opens up a new way for further development of ganoderma spores.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention discloses an imidazo [4, 5-b] pyridine compound capable of blocking mRNA translation of tumor cells and an application of the imidazo [4, 5-b] pyridine compound in preparation of antitumor drugs for blocking mRNA translation of tumor cells, and the imidazo [4, 5-b] pyridine compound has a structure shown in a formula (I) or a pharmaceutically acceptable salt of the imidazo [4, 5-b] pyridine compound. The mRNA translation of cancer promoting protein is crucial to the occurrence and development of malignant tumors, but a small molecular compound for targeted inhibition of mRNA translation is lacked clinically at present. The invention provides an imidazo [4, 5-b] pyridine compound, which can be combined with a translation initiation factor eIF4A and inhibit the ATP-dependent RNA helicase function of the translation initiation factor eIF4A so as to block the translation of mRNA and present proliferation inhibition and apoptosis promotion functions in various tumor cells. # imgabs0 #

The invention provides a bacterial outer membrane vesicle presenting Stoppin peptide as well as a construction method and application of the bacterial outer membrane vesicle, and relates to the technical field of biological medicines. According to the invention, a fusion protein ClyA-Stoppin is firstly designed and synthesized, and the fusion protein ClyA-Stoppin is displayed on the surface of the bacterial outer membrane vesicle by using a genetic engineering technology, so that the engineered bacterial outer membrane vesicle W-Stoppin OMV for targeting presentation of Stoppin peptide is successfully constructed. The W-Stoppin OMV provided by the invention has a remarkable inhibition effect on invasion and migration of tumor cells and can be used for remarkably promoting apoptosis of the tumor cells. According to the present invention, with the Stoppin monopeptide, the problems of insufficient Stoppin cell penetrability and difficult intracellular delivery are effectively solved, compared with the Stoppin monopeptide, the Stoppin monopeptide shows the excellent anti-tumor effect, and the migration inhibition, the invasion inhibition and the apoptosis promotion effects on the tumor cells are significantly increased. The W-Stoppin OMV provided by the invention has huge application potential in the aspect of preparation of anti-tumor drugs.

The invention discloses application of combination of okannin and epirubicin in prevention and / or treatment of colon cancer, relates to the technical field of biological medicine, and is technically characterized in that a pharmaceutical composition comprises okannin and epirubicin, the preferable molar ratio is 15: 1 or 7.5: 1, and the pharmaceutical composition aims to reduce the dosage of epirubicin, reduce toxic and side effects and enhance the curative effect through a synergistic effect. The invention also comprises a method for detecting the influence of the pharmaceutical composition on colon cancer cell viability and apoptosis, and an animal model for evaluating the influence on the tumor growth of a colon cancer tumor-bearing mouse. The pharmaceutical composition disclosed by the invention can be used for remarkably inhibiting the proliferation of colon cancer cells and enhancing the apoptosis promoting effect of epirubicin, and shows a good anti-tumor effect and relatively low visceral organ toxicity in an animal model. The invention provides a safe and effective new treatment strategy for colon cancer patients.

The invention relates to a gene and a plasmid of a humpback perch apoptosis regulator Bad and application of the gene and the plasmid, and belongs to the field of molecular biology, and the sequence of cDNA nucleotide of the humpback perch apoptosis regulator Bad is as shown in SEQ ID NO.1. The invention also provides a construction method of an eukaryotic expression plasmid of the humpback perch apoptosis regulator Bad, and a construction method of the eukaryotic expression plasmid of the humpback perch apoptosis regulator Bad. It is verified that the constructed eukaryotic expression vector has an apoptosis promoting effect on humpback perch cells, and after the humpback perch apoptosis regulatory factor Bad eukaryotic expression plasmid is injected into a fish body, bacterial reproduction can be remarkably inhibited, and a remarkable immune protection effect is achieved.

The invention provides an application of phosphatidylcholine 36: 1 in prevention and treatment of senescence cognitive impairment, and particularly relates to an application of phosphatidylcholine 36: 1 or a pharmaceutical composition containing phosphatidylcholine 36: 1 in preparation of drugs for prevention and / or treatment of senescence cognitive impairment. The phosphatidylcholine 36: 1 can improve the level of superoxide dismutase and glutathione peroxidase in the brain of the mouse and reduce the lipid oxidation level at the same time. After the phosphatidylcholine 36: 1 is used for treatment, the levels of inflammatory factors interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in the brain are obviously reduced. Meanwhile, neurotransmitter disorder in brains of senescent mice can be remarkably improved. After qRT-PCR analysis is carried out in the brain of a mouse, it is found that after phosphatidylcholine 36: 1 treatment, the senescence gene level is remarkably reduced, the pro-apoptosis gene level is remarkably reduced, and the anti-apoptosis gene level is remarkably increased. And after in vitro administration of phosphatidylcholine 36: 1 to mouse hippocampal neuronal cells, no cytotoxicity is found. Therefore, the phosphatidylcholine 36: 1 can be used for preventing and treating senescence cognitive impairment.

The invention relates to the technical field of biological medicines, in particular to a polypeptide targeting B cell lymphoma cells, a targeting effect conjugate and application of the polypeptide and the targeting effect conjugate. Wherein the peptide chain length of the polypeptide targeting the B-cell lymphoma cells is 12 amino acids, and the polypeptide is selectively and specifically combined with the B-cell lymphoma cells. The targeting effect conjugate is formed by connecting polypeptide and pro-apoptotic peptide through a connecting peptide. The pro-apoptotic peptide can induce programmed death of target cells by destroying a mitochondrial membrane structure. The molecular weight of the polypeptide is small, the chemical synthesis process is simple, convenient and efficient, high consistency between different batches of products can be ensured in the synthesis process, and a guarantee is provided for subsequent quality control. The small molecular structure is also convenient for sequence optimization and terminal modification, can create extremely favorable conditions for subsequent structure-function relationship research and pharmaceutical development work, and is helpful for accelerating the research and development process of novel therapeutic drugs.

The invention relates to the technical field of microorganisms, and particularly discloses a lactobacillus plantarum R202448 and application thereof in resisting helicobacter pylori, the lactobacillus plantarum R202448 is preserved in China General Microbiological Culture Collection Center on June 27, 2025, and the preservation number is CGMCC NO. The lactobacillus plantarum is located in Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing, has a preservation number of CGMCCNO: 31101, and is classified and named as lactobacillus plantarum R202448. According to the plant lactobacillus R202448 and the metabolite thereof disclosed by the invention, on the basis of inhibiting an H.pylori biological membrane and reducing the activity of the H.pylori, the damage and apoptosis promoting effects of the H.pylori on gastric mucosa epithelial cells can be effectively inhibited, so that the occurrence of the H.pylori is effectively inhibited, and the functions of the gastric mucosa epithelial cells are protected.

The invention discloses a plant lactobacillus and application thereof in relieving aflatoxin B1 induced liver injury, and relates to the technical field of microorganisms. The lactobacillus plantarum disclosed by the invention is lactobacillus plantarum TY-1, and the preservation number of the lactobacillus plantarum TY-1 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 20251682. The lactobacillus plantarum TY-1 disclosed by the invention has the advantages that the lactobacillus plantarum TY-1 is a lactobacillus plantarum TY-1, and the preservation number of the lactobacillus plantarum TY-1 in the China Center for Type Culture Collection (CCTCC); the bacterial strain has bacteriostatic activity and better oxidation resistance, and can effectively reduce the level of proinflammatory factors in serum, down-regulate the relative expression of pro-apoptosis genes and reduce the apoptosis of liver cells, thereby effectively relieving the damage to the liver caused by exposure to aflatoxin B1.

The present disclosure relates to a novel-peptide-based anticancer immunotherapeutic agent, and to use, as an anticancer immunotherapeutic agent, of melittin, a variant thereof, analogues thereof, or a conjugate in which a drug is linked thereto. The melittin, the variant thereof or the analogues thereof, of the present disclosure, specifically bind to ITGB2, which is expressed on the cell membrane of M2 tumor-associated macrophages, so as to kill the M2 tumor-associated macrophages, and a conjugate in which a pro-apoptotic peptide or an anticancer drug is conjugated as a drug to the melittin, the variant thereof, or the analogues thereof remarkably increases apoptotic effects of the M2 tumor-associated macrophages, and thus can be used as an anticancer composition for suppressing tumor growth and metastasis.

The invention discloses a functional small molecule peptide based on eggshell membrane peptide and application of the functional small molecule peptide in drug delivery, and belongs to the field of biological medicine. The invention relates to a functional small molecule peptide based on eggshell membrane peptide, which has pH responsiveness, can target liver cancer, can be prepared into a drug-loaded self-assembly body, and has a structural formula shown in Figure 1. The invention designs a novel small molecule peptide, develops a novel combined treatment scheme of a COX-2 inhibitor and a chemotherapeutic drug, and combines the anti-proliferation effect of DOX and the pro-apoptosis effect of CXB, so as to improve the therapeutic effect of the CXB. The activity of COX2 and the activation of hepatic stellate cells are inhibited, and the synergistic effect of resisting liver cancer is realized. Especially, the pH responsiveness of the experimental peptide Pep is utilized, morphology transformation occurs in a subacid environment, drug excretion and liver cancer proliferation are inhibited, and the functional small molecule peptide capable of enhancing the effect and reducing the toxicity provides a new treatment choice for liver cancer patients.

The present invention relates to CD117 targeted LNP molecules for delivery of pro-apoptotic mRNA to hematopoietic stem cells (HSCs) and methods of use thereof for preconditioning a subject for hematopoietic stem cell therapy or to deplete the subject's HSC population for the treatment of a disease or disorder.

The present invention discloses a polypeptide drug conjugate, a drug delivery system, a drug combination system and an application for synergistically enhancing tumor immunotherapy. The structural formula of the polypeptide drug conjugate is: P-L-D, wherein P is a polypeptide, D is a drug, and L is a cleavable chemical linker. The polypeptide is a pro-apoptotic polypeptide, and the drug is an indoleamine 2,3-dioxygenase (IDO) inhibitor. The polypeptide drug conjugate is prepared into nanoparticles by simple self-assembly and can be used for multiple tumor immunotherapies in vivo and in vitro. On the one hand, it can achieve the cleavage of tumor cells by the pro-apoptotic polypeptide and induce immunogenic cell death. At the same time, the combined IDO enzyme inhibitor can reverse the IDO enzyme-mediated immune metabolic pathway at the cellular level to relieve the inhibition of the immune microenvironment, and has a synergistic and enhanced tumor immunotherapy effect, and has good application prospects in the field of drug delivery.

The present application provides a derivative with a repaglinide tetravalent platinum structure and a preparation method and use thereof, the compound with the repaglinide tetravalent platinum structure is shown as general formula (I), wherein, selected from cisplatin or oxaliplatin; L is hydroxyl or a series of repaglinide platinum (IV) compounds targeting p53 pathway described in the present application, which shows good anti-proliferation and anti-metastasis activity in vitro and in vivo. The severe DNA damage caused by platinum core can up-regulate the expression of p53, and repaglinide (RPG) can also effectively promote the secretion of p53 through the lumican / p53 / p21 pathway. The present application designs and synthesizes a series of repaglinide tetravalent platinum derivatives, which can start mitochondrial-mediated apoptosis through the Bcl-2 / Bax / caspase-3 pathway. Subsequently, with the up-regulation of p53, the compound can effectively activate pro-apoptotic autophagy, inhibit the epithelial-mesenchymal transition (EMT) process, and then inhibit tumor angiogenesis by inhibiting COX-2, MMP9 and VEGFA. The compound can also increase the number of CD3 + And CD8 + T cells in tumors by blocking immune checkpoint PD-L1, and stimulate anti-tumor immunity. The above multiple anti-tumor mechanisms synergistically inhibit the proliferation and metastasis of tumor cells.

This invention relates to the fields of microbiology and biomedicine, and particularly to a strain of *Lactobacillus brittlemi* SYSU-32 and its application in tumor treatment. This invention cultured and isolated a strain of *Lactobacillus brittlemi* (SYSU-32). Limosilactobacillus pontis SYSU-32 was deposited on September 15, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 35919. This strain can increase CD8+ in the tumor microenvironment. + Infiltration of T cells and cytotoxic T cells inhibits the progression of colorectal cancer. Furthermore, the combination of *Lactobacillus bridgedii* SYSU-32 with the chemotherapy drug oxaliplatin enhances the pro-apoptotic effect of oxaliplatin, further inhibiting tumor progression and metastasis.

The invention belongs to the technical field of biological medicines, and discloses application of nigrum fruit-sourced nano-vesicles in preparation of medicines / health-care products for preventing and / or treating prostatic cancer. Purified nigrum fruit source nano-vesicles are stably extracted from nigrum fruits, the nigrum fruit source nano-vesicles are natural in ingredients, free of toxic and side effects and good in biocompatibility and safety, in-vivo and in-vitro experiments prove that the nigrum fruit source nano-vesicles have strong prostatic cancer proliferation and migration inhibition effects and apoptosis promotion effects, and the tumor inhibition effect of the nigrum fruit source nano-vesicles is proved in mouse animal experiments. The solanum nigrum fruit-sourced nano-vesicles can be orally taken and absorbed, have no tissue or immunological rejection, are expected to become important materials for preparing drugs for preventing and / or treating prostatic cancer, and have wide application prospects.

The application belongs to the technical field of biological medicine, and particularly relates to application of an imidazoquinazoline small-molecule compound or a pharmaceutically acceptable salt thereof shown in formula (I) in preparation of a drug for treating KRAS mutant gastrointestinal tumors, wherein R is as described in the claims and the specification. The imidazoquinazoline compound can selectively inhibit proliferation, migration and invasion of KRAS mutant gastrointestinal tumor cells, and induce cell cycle arrest and apoptosis. Specifically, the compound exerts an anti-tumor effect by inhibiting the binding of p-ERK2 and p53, restoring p53 transcriptional activity, and up-regulating the expression of a pro-apoptotic gene PUMA downstream of p53. The mechanism of action is different from that of traditional KRAS or MEK inhibitors, and provides a new treatment option for KRAS mutant gastrointestinal tumor patients.

The present invention discloses Lactobacillus plantarum KSFY202409 and its use for colorectal cancer, and relates to the technical field of microorganisms. Lactiplantibacillus plantarum ), with a deposit number of CGMCC No. 31103. The present invention also provides the use of the above-mentioned plant lactobacillus in the preparation of a product for preventing or treating colorectal cancer. The plant lactobacillus of the present invention can effectively reduce the incidence of tumors, improve rectal tissue pathological damage, reduce the level of inflammatory factors, down-regulate the expression of anti-apoptotic factors, and up-regulate the expression of pro-apoptotic factors. It has a significant effect in intervening in the occurrence and development of inflammation-related colorectal cancer in mice, and can be used as a potential strain for preventing and assisting in the treatment of inflammation-related colorectal cancer, and has broad application prospects.

The invention relates to the technical field of medicines, and particularly discloses a pharmaceutical composition based on an IRF7-PTEN signal axis and application of the pharmaceutical composition in spinal cord injury. According to the application, a plurality of spinal cord injury single cell sequencing data sets are integrated, and the interferon regulatory factor 7, namely IRF7, is screened and verified to be a key hub gene for regulating and controlling apoptosis of astrocytes. Knock-down IRF7 significantly inhibits astrocyte apoptosis induced by etoposide, and rotation IRF7 can reverse the effect. In mechanism, the IRF7 promotes cell apoptosis by negatively regulating a PTEN pathway, and the PTEN inhibitor SF1670 can block the IRF7 overexpression mediated apoptosis promoting effect. On the basis, the invention provides a pharmaceutical composition taking the signal axis as a target spot, and the active ingredient of the pharmaceutical composition can be an IRF7 inhibitor or a PTEN inhibitor; the invention also discloses application of the inhibitor in preparation of drugs for treating spinal cord injury. The application provides a new target spot and an effective intervention strategy for treatment of spinal cord injury.

The invention discloses a composite single-cell protein feed for improving anti-infection immunity of micropterus salmoides and application of the composite single-cell protein feed, and belongs to the technical field of feed preparation. The feed comprises composite single-cell protein for replacing 40-100% of fish meal, and the composite single-cell protein comprises chlorella and clostridium ethanol protein in a mass ratio of 1: (4-5). The compound single-cell protein is adopted to replace part of fish meal in the feed, so that the cost of the feed can be remarkably reduced, the anti-infection immunity of the micropterus salmoides to aeromonas hydrophila can be improved, expression down-regulation of a pro-apoptosis gene casp8 and an antigen presentation related gene mhci in the micropterus salmoides can be promoted, and the apoptosis resistance of the micropterus salmoides can be improved. The expression up-regulation of the anti-apoptosis gene bcl2l1 and the anti-ferroptosis gene gpx4a is promoted. In addition, the liver metabolism function of the micropterus salmoides can be improved, and lipid metabolism is promoted.

The present invention relates to a combination of an HDAC inhibitor and statins for use in the treatment of pancreatic cancer. Preferably the invention relates to a combination of valproic acid (VPA) or any of its salts and simvastatin (SIM). The combination of the invention synergistically improves the anti-proliferative and pro-apoptotic effect of conventional chemotherapy, as gemcitabine / taxol.

The invention discloses application of polyphyllin VII in preparation of a bladder cancer chemotherapy sensitizer, and experiments prove that the polyphyllin VII plays a sensitizing role through the following mechanisms: (1) dose-dependent inhibition of Akt pathway activity, reduction of the levels of p-PI3K, p-AKT, p-mTOR, p-GSK3beta and p-P70S6K, and up-regulation of P21 expression; (2) inhibiting the protein expression of SREBP1, ACC, FASN and SCD1 of the components of the SREBP1 signal channel; and (3) up-regulating protein expression of apoptosis markers c-PARP (poly-ADP-ribose polymerase) and c-cas-7. In T24CDDP drug-resistant cells, the polyphyllin VII significantly increases the apoptosis rate, the effect can be weakened by an Akt activator SC79, the cytotoxicity and apoptosis-promoting activity of the cis-platinum are enhanced in a dose-dependent manner, animal experiments show that the polyphyllin VII and the cis-platinum are combined for use to generate a strong synergistic effect, the drug interaction coefficient is 0.45, obvious toxicity is not caused, and the polyphyllin VII and the cis-platinum are combined for use. The invention provides a safe and effective new strategy for overcoming cis-platinum drug resistance of bladder cancer.

The present invention relates to activators of caspase-8 / c-FLIPL dimerization and their use in enhancing the pro-apoptotic activity of the heterodimer and cancer therapy.

The invention relates to the field of treatment of neurodegenerative diseases, and discloses a method for treating ALS through intrathecal targeted drug delivery of an extremely low dose of KN93 after a disease is attacked, and the method comprises the following steps: screening ALS model objects showing disease symptoms; within 24 hours after the ALS model object is confirmed to be diseased, the KN93 pharmaceutical composition is applied to the space in the spinal cord sheath for a single time; and evaluating the curative effect of the ALS model object after the KN93 pharmaceutical composition is applied. In a treatment window period within 24 hours after an ALS model object is attacked, an extremely low dose of KN93 pharmaceutical composition is directly delivered to a spinal cord intrathecal gap in an intrathecal administration manner, so that the medicine can quickly enter cerebrospinal fluid circulation and is enriched in a central lesion target region in a targeted manner without penetrating through a blood brain barrier and a blood-spinal cord barrier; therefore, pathological excessive activation of CaMKII is specifically inhibited, and injury mechanisms such as neuronal excitatory toxicity, calcium overload and pro-apoptosis pathway mediated by CaMKII are blocked.

The invention provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, and provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, which has the advantages that by increasing the concentration of amentotaxus biflavone, the number of bladder cancer cells is gradually reduced, the cells are shrunk, nuclear shrinkage of different degrees is caused, the activity, proliferation, invasion and migration of bladder cancer T24 cells and bladder cancer 5637 cells are inhibited, and the bladder cancer is treated. The PI3K / AKT / NF-kappa B pathway promotes the expression of a pro-apoptosis gene Bax in bladder cancer cells, inhibits the expression of an apoptosis inhibitor gene Bcl-2, inhibits the proliferation of the bladder cancer cells by inducing G1 phase retardation of the bladder cancer cells, induces and reduces the expression of PI3K, AKT and NF-kappa B proteins in cell nucleuses through the PI3K / AKT / NF-kappa B pathway, and induces the apoptosis of the bladder cancer cells. The invention belongs to the field of medicine.

The invention discloses application of an equivalent component group combined protein sensitizer of Sangui decoction in tumor drug resistance, and belongs to the technical field of tumor treatment. The equivalent component group of the three-component scutellaria baicalensis decoction comprises baicalin and sophocarpidine, and the protein sensitizer is StcE mucoprotease. The StcE mucoprotease has rapid and remarkable growth inhibition and apoptosis promotion activity on cancer cells, the dosage of chemotherapeutic drugs in tumor cells can be greatly reduced under the extremely low and non-toxic dosage, baicalin and sophocarpidine have various pharmacological effects of resisting inflammation, resisting oxidation, resisting tumors and the like and have huge potential in the aspect of drug resistance reversion, and the application has a good application prospect. The two are combined for reversing tumor drug resistance, so that the killing effect of chemical drugs can be promoted, the use amount of the chemical drugs is effectively reduced, and the killing effect of the chemical drugs on cells is improved.

The invention provides brain polypeptide raw materials capable of benefiting intelligence and strengthening brain, functional food and a preparation method of the brain polypeptide raw materials, and belongs to the technical field of functional food. The preparation method comprises the following steps: S1, pretreatment; s2, performing primary hydrolysis: adjusting the pH value of the pre-hydrolysate to 6.5-7.5, adding neutral protease with the addition amount being 3.5-4.5% of the mass of the bovine brain protein, performing enzymolysis at 50-60 DEG C for 1-3 hours, and performing enzyme deactivation to obtain first hydrolysate; s3, second hydrolysis: adjusting the pH value of the first hydrolysate to 6.0-7.0, adding papain with the addition amount being 1.0-3.0% of the mass of the bovine brain protein, carrying out enzymolysis at 45-65 DEG C for 1.5-2.5 h, and carrying out enzyme deactivation to obtain a second hydrolysate; and S4, performing post-treatment to obtain the brain polypeptide raw material powder. The brain polypeptide raw material can significantly remove DPPH free radicals and ABTS free radicals, inhibit the activity of acetylcholin esterase, repair PC12 nerve cells, inhibit the expression of a pro-apoptosis gene Bax and promote the expression of an anti-apoptosis gene Bcl-2, jointly exert the effects of benefiting intelligence, strengthening brain and protecting cranial nerves, and can be used as a functional factor to be applied to a functional product for benefiting intelligence and strengthening brain.